120 Participants NeededMy employer runs this trial

Hyperbaric Oxygen Therapy for Post-COVID Syndrome

(RECLAIM-HBOT Trial)

JS
AJ
RC
Overseen ByRECLAIM CONTACT RECLAIM contact line
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University Health Network, Toronto
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores whether hyperbaric oxygen therapy (HBOT) can improve cognitive symptoms like brain fog and fatigue in individuals with Long COVID. HBOT involves breathing pure oxygen in a pressurized environment, which may address blood vessel issues believed to cause these symptoms. The trial includes two groups: one receiving HBOT and the other a sham treatment, which mimics the experience without the therapeutic effect. Individuals with lingering COVID-19 symptoms for at least three months, including cognitive issues, might be suitable for this trial. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research on Long COVID treatments.

What prior data suggests that Hyperbaric Oxygen Therapy is safe for post-COVID syndrome?

Research has shown that Hyperbaric Oxygen Therapy (HBOT) is generally safe with few risks, and most patients tolerate it well. Studies, including a detailed review, have confirmed its safety for treating Long COVID symptoms. Specifically, one study found that symptoms improved and lasted for a year after treatment, demonstrating its safety and potential benefits.

However, while HBOT is commonly used and well-tolerated, some individuals might experience minor side effects. These can include ear discomfort from pressure changes, similar to what one might feel on an airplane. Overall, the evidence supports HBOT as a safe option for those considering joining a trial for Long COVID treatment.12345

Why are researchers excited about this trial?

Unlike current treatments for post-COVID syndrome, which often include medications and physical therapy to manage symptoms, hyperbaric oxygen therapy (HBOT) is unique because it delivers 100% oxygen at higher-than-normal air pressure. This approach is thought to enhance oxygen delivery to tissues, potentially speeding up recovery and improving overall function. Researchers are excited about HBOT because it targets the root cause by improving cellular oxygenation, which may lead to more effective and quicker symptom relief compared to standard care options.

What is the effectiveness track record for Hyperbaric Oxygen Therapy in treating post-COVID cognitive dysfunction?

Research has shown that Hyperbaric Oxygen Therapy (HBOT) can benefit people with Long COVID, particularly in alleviating symptoms like fatigue, cognitive difficulties, and muscle pain. In this trial, participants will receive either HBOT or a sham treatment. Studies have found that patients who underwent HBOT experienced lasting improvements in cognitive skills, focus, and overall quality of life, even a year post-treatment. Specifically, one study noted significant enhancements in both mental and physical health. The therapy increases oxygen levels in the body, promotes the growth of new blood vessels, and reduces swelling, which are believed to be crucial in treating Long COVID symptoms. Overall, HBOT appears to be a promising treatment option for those suffering from post-COVID syndrome.12367

Who Is on the Research Team?

RK

Rita Katznelson, MD

Principal Investigator

University Health Network, Toronto

AM

Angela M Cheung, MD, PhD

Principal Investigator

University Health Network, Toronto

Are You a Good Fit for This Trial?

Inclusion Criteria

I tested positive for COVID-19 over 3 months ago or was presumed to have had it after October 15, 2019.
I have received standard treatments for at least 4 weeks before joining the trial.
I still have symptoms from COVID-19.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Hyperbaric Oxygen Therapy (HBOT) or sham treatment for 8 weeks, with sessions occurring once daily, five times a week

8 weeks
40 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments including cognitive testing and symptom tracking

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Hyperbaric Oxygen Therapy

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: Hyperbaric oxygen therapyExperimental Treatment1 Intervention
Group II: Hyperbaric oxygen shamPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University Health Network, Toronto

Lead Sponsor

Trials
1,555
Recruited
526,000+

Citations

Safety and Efficacy of Hyperbaric Oxygen Therapy for Long ...

The overall hypothesis to be evaluated is that hyperbaric oxygen (HBO2) alleviates symptoms associated with Long COVID. Detailed Description. Phase II Clinical ...

Hyperbaric oxygen therapy for long COVID: a prospective ...

Longitudinal follow up of HBOT patients in this trial showed persistent improvement in patient-reported outcomes one year after treatment.

Hyperbaric Oxygen Therapy on Long COVID Symptoms - PMC

They suggested that HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms and cardiopulmonary functions. HBOT is a ...

Hyperbaric Oxygen Therapy for Long COVID: Evidence ...

Durable benefits observed up to one-year post-treatment, with greatest improvements in most disturbed domains. Controlled studies demonstrate ...

Hyperbaric oxygen effectively addresses the ...

Hyperbaric Oxygen Therapy (HBO) treated patients had significant improvement in global cognitive function, fatigue, attention, executive function, energy, ...

Efficacy and safety of hyperbaric oxygen therapy for long ...

This systematic review and meta-analysis aim to better investigate the overall efficacy and safety of HBOT for long COVID.

Hyperbaric Oxygen Treatment of Long Covid

Durable benefits observed up to one-year post-treatment, with greatest improvements in most disturbed; Controlled studies demonstrate the safety ...